Trial Profile
A placebo-controlled study for SPM 962 in RLS patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2016
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 15 Jan 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 14 May 2008 New trial record.